ATMA Journey

On February 3, 2023, Australia made a big move in mental health care. The Therapeutic Goods Administration (TGA) decided to allow the use of MDMA for PTSD and Psilocybin for treatment-resistant depression starting July 1, 2023. This means these drugs can now be used in a controlled setting to help people who haven't found relief with other treatments. This change is a big deal because it officially recognizes the potential of psychedelic-assisted therapy in Australia . However, this new therapy option presents a challenge: we need more trained professionals. Psychiatrists are currently the only ones allowed to prescribe these treatments, and they must go through a specific approval process. This includes training in how to manage and deliver these therapies safely. The need for Psychedelic-Assisted Therapy Training for Physicians is clear. With only about 3,700 psychiatrists in Australia, and many already swamped with long waitlists, training more healthcare workers could reall...

As the conversation around mental health treatment evolves, psilocybin therapy emerges as a promising avenue for addressing many psychiatric conditions. With the increasing acceptance of this therapy, the role of a qualified Psilocybin Therapy Training Provider becomes vital. ATMA, a leader in psychedelic therapy, stands at the front of this movement. Psilocybin, the psychoactive compound found in magic mushrooms, has been studied for its potential in treating depression, anxiety, PTSD, and more. The effectiveness of psilocybin therapy hinges not just on the compound itself but significantly on the therapeutic setting and the knowledge of the facilitator. This is where a Psilocybin Therapy Training Provider like ATMA comes into play, ensuring that practitioners are well-prepared to guide patients through their impactful journeys safely and effectively. Psilocybin Therapy Training at ATMA is designed to equip therapists with the knowledge and skills needed to administer this treatm...